Matches in Wikidata for { <http://www.wikidata.org/entity/Q93023272> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- Q93023272 description "artículu científicu espublizáu en xunu de 2019" @default.
- Q93023272 description "scientific article published on 25 June 2019" @default.
- Q93023272 description "wetenschappelijk artikel" @default.
- Q93023272 description "наукова стаття, опублікована 25 червня 2019" @default.
- Q93023272 name "Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use" @default.
- Q93023272 name "Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use" @default.
- Q93023272 type Item @default.
- Q93023272 label "Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use" @default.
- Q93023272 label "Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use" @default.
- Q93023272 prefLabel "Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use" @default.
- Q93023272 prefLabel "Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use" @default.
- Q93023272 P1433 Q93023272-299A6900-9AC4-433C-B6FC-DEC8141195E9 @default.
- Q93023272 P1476 Q93023272-01F64AF2-C762-4440-AD8E-0C5D56774FBD @default.
- Q93023272 P2093 Q93023272-2FB23EBB-7AB7-4ECE-B538-8F2383CA50ED @default.
- Q93023272 P2093 Q93023272-354969C3-03B0-4779-9706-B6150897C60D @default.
- Q93023272 P2093 Q93023272-65AE1CC3-4898-4ED6-9B08-4DA14243301C @default.
- Q93023272 P2093 Q93023272-964FAEDA-0890-4C2E-8CD4-49EF2B500DF0 @default.
- Q93023272 P2093 Q93023272-AEF42BD6-68B1-470B-838B-0200BD955870 @default.
- Q93023272 P2093 Q93023272-CA7DA743-0876-4270-A3BE-E88B3B429358 @default.
- Q93023272 P2093 Q93023272-D0649595-38EF-4641-B06A-921E330DAB4E @default.
- Q93023272 P2093 Q93023272-D2EC4D40-C576-4501-B21C-54411E903109 @default.
- Q93023272 P2093 Q93023272-D8DAE95A-05DE-4093-B31D-A8D53EC0F553 @default.
- Q93023272 P2093 Q93023272-DE5106B1-03A8-4386-A3A2-5A5B9534A92A @default.
- Q93023272 P2093 Q93023272-E635C6A7-004A-4A44-8E26-FE708569F701 @default.
- Q93023272 P2093 Q93023272-F4691308-850D-4003-A2F5-1246FE92B0F3 @default.
- Q93023272 P2093 Q93023272-FE39AC31-B371-472F-AEAB-B5783E8E7F78 @default.
- Q93023272 P304 Q93023272-2CA33EC0-1FE0-4AD9-BD39-384B133BAB24 @default.
- Q93023272 P31 Q93023272-3949F773-2CFD-42EA-93EB-50374FCBD884 @default.
- Q93023272 P356 Q93023272-68992B2A-6B79-43DE-9D6A-E7218D32A225 @default.
- Q93023272 P433 Q93023272-F5E419CD-C86A-4327-BE59-C299A63EE764 @default.
- Q93023272 P478 Q93023272-E12FA6E9-955F-4334-AD87-167D9234A4C3 @default.
- Q93023272 P50 Q93023272-60DB6351-11FA-4863-B163-409F86F02B20 @default.
- Q93023272 P50 Q93023272-65CCC6D3-1721-44F7-AC6A-0DBEFCF52235 @default.
- Q93023272 P50 Q93023272-7C29F4D2-E506-465F-842B-1B72AB59C9D7 @default.
- Q93023272 P50 Q93023272-98B7A4D1-76ED-4720-AAD3-3F4A3922F3A8 @default.
- Q93023272 P50 Q93023272-E4B6C37D-9BAD-431D-A519-B5B4C54C5A2A @default.
- Q93023272 P50 Q93023272-FA0CBA9F-6EAD-474A-AD84-35F0DD3BD484 @default.
- Q93023272 P577 Q93023272-3D2BBC76-107A-4722-898B-2668C23E20EA @default.
- Q93023272 P698 Q93023272-4DC7797D-B2F0-4BDF-874B-A6B0E9149E42 @default.
- Q93023272 P921 Q93023272-04B37E08-61CF-42CB-827A-B46EA9538F4B @default.
- Q93023272 P921 Q93023272-05E6D098-E985-4EA2-B0C7-75D9466595A5 @default.
- Q93023272 P921 Q93023272-53F36821-42F1-41BC-96BA-EC35AFD1C3E0 @default.
- Q93023272 P356 1078-0432.CCR-18-3944 @default.
- Q93023272 P698 31239321 @default.
- Q93023272 P1433 Q332253 @default.
- Q93023272 P1476 "Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use" @default.
- Q93023272 P2093 "A Dimitrios Colevas" @default.
- Q93023272 P2093 "Caroline Even" @default.
- Q93023272 P2093 "Fernando Concha-Benavente" @default.
- Q93023272 P2093 "Jerome Fayette" @default.
- Q93023272 P2093 "Joel Guigay" @default.
- Q93023272 P2093 "Kevin J Harrington" @default.
- Q93023272 P2093 "Li Li" @default.
- Q93023272 P2093 "Lisa Licitra" @default.
- Q93023272 P2093 "Mark Lynch" @default.
- Q93023272 P2093 "Nabil F Saba" @default.
- Q93023272 P2093 "Peter Brossart" @default.
- Q93023272 P2093 "Robert Haddad" @default.
- Q93023272 P2093 "Shanmugasundaram Ramkumar" @default.
- Q93023272 P304 "5221-5230" @default.
- Q93023272 P31 Q13442814 @default.
- Q93023272 P356 "10.1158/1078-0432.CCR-18-3944" @default.
- Q93023272 P433 "17" @default.
- Q93023272 P478 "25" @default.
- Q93023272 P50 Q107015339 @default.
- Q93023272 P50 Q38328358 @default.
- Q93023272 P50 Q73567428 @default.
- Q93023272 P50 Q89747698 @default.
- Q93023272 P50 Q92533579 @default.
- Q93023272 P50 Q94702986 @default.
- Q93023272 P577 "2019-06-25T00:00:00Z" @default.
- Q93023272 P698 "31239321" @default.
- Q93023272 P921 Q18348812 @default.
- Q93023272 P921 Q18975728 @default.
- Q93023272 P921 Q420296 @default.